Industry Insights on Research and Innovation Seminars

In this monthly Industry Insights on Research and Innovation Seminar (IIRIS) series, presented by Technology Opportunities & Ventures (TOV), experts from innovative startups will join us to discuss how their companies are using cutting-edge science to develop the next generation of therapeutics, diagnostics, medical devices, and more. They will also share insights into industry trends and career opportunities, and answer questions from attendees. The events are free and open to the NYU community, and a boxed lunch is provided.

October's speaker is Jennifer Beecham, President and Co-Founder of Rho Bio. Rho Bio was founded by scientists Eric Song, Akiko Iwasaki, Aaron Ring, and Jonathan Kipnis, pioneers in immunology and lymphatic biology. The company is pioneering therapeutics that selectively activate the lymphatic system. Its engineered VEGFR-3–specific proteins uniquely stimulate lymphatic pumping and vessel growth without engaging the vascular system. The company’s mission is to unlock this untapped pathway to treat diseases of fluid imbalance and immune dysfunction, starting with neuro-ophthalmology and expanding into neurodegenerative, cardiovascular, metabolic, and autoimmune conditions.

Full speaker bio:

Jennifer Beecham is President and Co-Founder of Rho Bio. Jennifer leads translational strategy and preclinical operations at the Blavatnik Fund at Yale Ventures. Prior to Yale Ventures, Jennifer spent almost a decade with Reata Pharmaceuticals in roles across finance, operations, and finally planning the launch of SKYCLARYS, the first therapy for Freidreich's ataxia. Jennifer holds a Master's and a Bachelor's in Bioengineering from the University of Pennsylvania.